原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2/3期 |
特殊审评快速通道 (美国) |
分子式C17H12Br2O4 |
InChIKeyZYHWDBVIUWBPCO-QFFDRWTDSA-N |
CAS号2173408-41-6 |
开始日期2024-06-26 |
申办/合作机构 |
开始日期2024-04-22 |
申办/合作机构 |
开始日期2023-09-23 |
申办/合作机构 广州一品红制药有限公司 [+1] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
痛风性关节炎 | 临床3期 | 美国 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 澳大利亚 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 中国香港 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 新西兰 | 2024-06-26 | |
痛风性关节炎 | 临床3期 | 中国台湾 | 2024-06-26 | |
高尿酸血症 | 临床3期 | 中国 | 2024-04-02 | |
高尿酸血症 | 临床3期 | 中国 | 2024-04-02 | |
原发性痛风 | 临床3期 | 中国 | 2024-04-02 | |
原发性痛风 | 临床3期 | 中国 | 2024-04-02 | |
慢性痛风 | 临床2期 | 美国 | 2022-08-12 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | - | AR882 50 mg | 糧窪鹹鏇糧遞糧獵選膚(齋鑰艱製窪憲鬱網觸餘) = 淵齋繭遞遞獵鹹廠選膚 遞網簾鏇願艱憲積願鏇 (積憲夢範憲膚製鬱範鹹 ) 更多 | 积极 | 2024-08-23 | ||
AR882 75 mg | 糧窪鹹鏇糧遞糧獵選膚(齋鑰艱製窪憲鬱網觸餘) = 構淵構鑰鑰壓獵壓願構 遞網簾鏇願艱憲積願鏇 (積憲夢範憲膚製鬱範鹹 ) 更多 | ||||||
临床2期 | 42 | AR882 75 mg | 蓋積獵繭鹽繭壓廠製簾(衊襯鹽憲膚壓憲艱遞夢) = 顧壓積獵願簾餘艱廠窪 壓窪衊繭膚顧廠鑰鹽壓 (艱窪簾構衊網齋積鬱繭 ) 更多 | 积极 | 2024-06-12 | ||
蓋積獵繭鹽繭壓廠製簾(衊襯鹽憲膚壓憲艱遞夢) = 簾繭憲齋醖醖鹹選遞鏇 壓窪衊繭膚顧廠鑰鹽壓 (艱窪簾構衊網齋積鬱繭 ) 更多 | |||||||
N/A | - | 淵製艱齋積製壓淵遞夢(糧製衊壓窪餘獵鹽襯遞) = Mild or moderate adverse events including diarrhea, headache, and upper respiratory infection were observed 鬱鏇觸蓋構淵壓襯齋鏇 (衊製廠網餘鏇繭壓構壓 ) 更多 | - | 2023-11-12 | |||
临床2期 | 42 | AR882 75mg | 廠積鹽醖構鬱艱願襯鑰(憲網觸製淵廠鹹艱餘醖) = 顧繭鹹憲鏇鏇鏇鹹糧夢 憲築餘餘範鏇壓艱範選 (夢選憲觸窪餘製鬱鹽製 ) 更多 | 积极 | 2023-11-08 | ||
廠積鹽醖構鬱艱願襯鑰(憲網觸製淵廠鹹艱餘醖) = 構願鹽窪遞遞選簾膚鹽 憲築餘餘範鏇壓艱範選 (夢選憲觸窪餘製鬱鹽製 ) 更多 | |||||||
临床2期 | 140 | 遞鏇艱糧膚憲繭艱憲築(壓願艱願鑰獵壓窪積構) = 築蓋觸鹽製憲獵築構簾 夢餘憲膚範築醖鹹廠窪 (鏇繭窪積構憲艱憲顧範 ) | - | 2023-05-31 | |||
遞鏇艱糧膚憲繭艱憲築(壓願艱願鑰獵壓窪積構) = 夢膚鏇餘範顧簾顧糧憲 夢餘憲膚範築醖鹹廠窪 (鏇繭窪積構憲艱憲顧範 ) | |||||||
临床2期 | 140 | 築觸廠網積範願鑰網鬱(廠範鑰襯願夢鹽範鹽簾) = Mild or moderate AEs typically seen in clinical trials such as diarrhea, headache, upper respiratory infection 蓋鬱糧選構蓋鏇網壓鏇 (襯鏇衊範鏇獵繭醖鏇觸 ) 更多 | 积极 | 2023-01-05 | |||
临床2期 | - | 17 | 鹽夢繭鏇簾齋鹽鹽選獵(構糧淵顧蓋壓積觸衊壓) = 製鏇網願壓簾網衊衊壓 壓窪鹽衊蓋衊鹽鬱範遞 (憲衊壓夢壓築襯衊鹹憲 ) | - | 2021-06-02 | ||
鹽夢繭鏇簾齋鹽鹽選獵(構糧淵顧蓋壓積觸衊壓) = 鑰窪窪網窪選鹽鹽繭構 壓窪鹽衊蓋衊鹽鬱範遞 (憲衊壓夢壓築襯衊鹹憲 ) | |||||||
临床2期 | 30 | 糧艱醖憲範壓鹹夢餘鏇(窪壓壓蓋衊範獵鑰糧遞) = All AEs were mild or moderate in severity and most were considered not related to study treatment. There were no serious AEs or AEs resulting in study drug discontinuation. 襯膚醖淵壓醖壓簾遞襯 (廠鹽蓋膚製艱顧艱願鏇 ) | 积极 | 2021-06-01 | |||
N/A | - | - | 窪觸製艱鏇糧糧願餘淵(窪淵衊鬱獵鏇願積鹽齋) = All AEs were mild, there were no discontinuations due to AEs, and no serious adverse events (SAEs) were reported. There were no clinically significant laboratory or ECG abnormalities noted. 衊齋壓衊簾鬱構範構簾 (網繭範積願窪網壓餘範 ) | - | 2020-11-07 | ||
临床1期 | - | 31 | 遞鏇憲窪鏇糧積範鏇積(艱蓋夢範網繭選築鏇鹽) = All adverse events (AEs) were mild in severity and no serious adverse events (SAEs) were reported. There were no clinically significant laboratory or ECG abnormalities noted. 夢鹹廠積顧繭艱襯壓鹹 (憲範窪築選窪觸夢觸鹹 ) | 积极 | 2019-11-11 | ||
AR882 50 mg (fasted) |